Animalcare Group Valuation
Is ANCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of ANCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: ANCR (£2.23) wird über unserer Schätzung des Fair Value (£2) gehandelt.
Deutlich unter dem Marktwert: ANCR über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ANCR?
Other financial metrics that can be useful for relative valuation.
| What is ANCR's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | UK£125.02m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 14.7x |
| PEG Ratio | 5.1x |
Price to Earnings Ratio vs Peers
How does ANCR's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.9x | ||
HIK Hikma Pharmaceuticals | 27.5x | 18.1% | UK£4.1b |
HCM HUTCHMED (China) | 28.6x | 18.2% | UK£2.3b |
BVXP Bioventix | 27.1x | 5.2% | UK£234.9m |
NIOX NIOX Group | 28.3x | 16.9% | UK£268.8m |
ANCR Animalcare Group | 108.4x | 20.9% | UK£126.2m |
Price-To-Earnings gegen Gleichaltrige: ANCR ist auf der Grundlage des Price-To-Earnings Verhältnisses (100.2x) im Vergleich zum Durchschnitt der Vergleichsgruppe (40x) teuer.
Price to Earnings Ratio vs Industry
How does ANCR's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: ANCR ist teuer, wenn man sein Price-To-Earnings Verhältnis (100.2x) mit dem European Pharmaceuticals Branchendurchschnitt (22.5x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is ANCR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 107.4x |
| Fair PE Ratio | 20x |
PM vs. Fair Ratio: ANCR ist teuer auf der Grundlage des Verhältnisses Price-To-Earnings (100.2x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (34.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | UK£2.08 | UK£3.20 +53.8% | 6.3% | UK£3.40 | UK£3.00 | n/a | 2 |
| Mar ’25 | UK£2.22 | UK£3.20 +44.1% | 6.3% | UK£3.40 | UK£3.00 | n/a | 2 |
| Feb ’25 | UK£1.78 | UK£3.20 +80.3% | 6.3% | UK£3.40 | UK£3.00 | n/a | 2 |
| Jan ’25 | UK£1.70 | UK£3.20 +88.2% | 6.3% | UK£3.40 | UK£3.00 | n/a | 2 |
| Dec ’24 | UK£1.75 | UK£3.20 +82.9% | 6.3% | UK£3.40 | UK£3.00 | n/a | 2 |
| Nov ’24 | UK£1.73 | UK£3.20 +85.5% | 6.3% | UK£3.40 | UK£3.00 | n/a | 2 |
| Oct ’24 | UK£1.83 | UK£3.20 +75.3% | 6.3% | UK£3.40 | UK£3.00 | n/a | 2 |
| Sep ’24 | UK£1.75 | UK£3.46 +97.4% | 4.5% | UK£3.61 | UK£3.30 | n/a | 2 |
| Aug ’24 | UK£1.73 | UK£3.46 +100.3% | 4.5% | UK£3.61 | UK£3.30 | n/a | 2 |
| Jul ’24 | UK£1.82 | UK£3.34 +84.0% | 1.2% | UK£3.38 | UK£3.30 | n/a | 2 |
| Jun ’24 | UK£1.82 | UK£3.34 +84.0% | 1.2% | UK£3.38 | UK£3.30 | n/a | 2 |
| May ’24 | UK£1.82 | UK£3.34 +83.5% | 1.2% | UK£3.38 | UK£3.30 | n/a | 2 |
| Apr ’24 | UK£1.58 | UK£3.34 +112.1% | 1.2% | UK£3.38 | UK£3.30 | UK£2.10 | 2 |
| Mar ’24 | UK£1.74 | UK£3.50 +101.1% | 4.3% | UK£3.65 | UK£3.35 | UK£2.22 | 2 |
| Feb ’24 | UK£1.80 | UK£3.50 +94.4% | 4.3% | UK£3.65 | UK£3.35 | UK£1.78 | 2 |
| Jan ’24 | UK£2.28 | UK£3.88 +70.3% | 5.8% | UK£4.10 | UK£3.65 | UK£1.70 | 2 |
| Dec ’23 | UK£2.25 | UK£3.88 +72.2% | 5.8% | UK£4.10 | UK£3.65 | UK£1.75 | 2 |
| Nov ’23 | UK£2.23 | UK£3.88 +74.2% | 5.8% | UK£4.10 | UK£3.65 | UK£1.73 | 2 |
| Oct ’23 | UK£2.53 | UK£3.88 +53.5% | 5.8% | UK£4.10 | UK£3.65 | UK£1.83 | 2 |
| Sep ’23 | UK£2.98 | UK£4.42 +48.4% | 1.9% | UK£4.50 | UK£4.33 | UK£1.75 | 2 |
| Aug ’23 | UK£2.78 | UK£4.42 +59.1% | 1.9% | UK£4.50 | UK£4.33 | UK£1.73 | 2 |
| Jul ’23 | UK£2.67 | UK£4.49 +68.0% | 0.3% | UK£4.50 | UK£4.47 | UK£1.82 | 2 |
| Jun ’23 | UK£3.03 | UK£4.49 +48.3% | 0.3% | UK£4.50 | UK£4.47 | UK£1.82 | 2 |
| May ’23 | UK£3.23 | UK£4.49 +39.1% | 0.3% | UK£4.50 | UK£4.47 | UK£1.82 | 2 |
| Apr ’23 | UK£3.35 | UK£4.49 +33.9% | 0.3% | UK£4.50 | UK£4.47 | UK£1.58 | 2 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, aber es gibt nicht genügend Analysten, die die Aktie beobachten, um eine statistische Sicherheit für eine Übereinstimmung zu ermitteln.